Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 30, 2024
Daily News
April 30, 2024
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
- PeptiDream to Start First-in-Human Trial for CAIX-Targeted Radiopeptide
April 30, 2024
- JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
- Sanofi Seeks COPD Nod for Dupixent in Japan
April 30, 2024
- Genmab Files ADC Tisotumab Vedotin for Cervical Cancer in Japan
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…